Irbesartan improves arterial compliance more than lisinopril

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 587-592

  Ali, Khalid ^a   Rajkumar, Chakravarthi ^a   Fantin, Francesco ^b   Schiff, Rebekah ^c   Bulpitt, Christopher J ^c  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Arterial compliance; Hypertension

Indexed keywords

IRBESARTAN; LISINOPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTERY COMPLIANCE; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; FEMORAL ARTERY; HUMAN; HYPERTENSION; MALE; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ARTERY; BLOOD PRESSURE; COMPARATIVE STUDY; COMPLIANCE (PHYSICAL); DRUG EFFECT; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CAROTID ARTERIES; COMPLIANCE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; RADIAL ARTERY; TETRAZOLES; TREATMENT OUTCOME;

EID: 70350493505     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s5690     Document Type: Article

References (30)

1. National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group. Hypertension. 1994;23:275-285.
2. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.
3. Dahlof B, Hansson L, Lindholm LH, Schersten B, Ekbom T, Wester PO. Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clin Exp Hypertens. 1993;15:925-939.
4. Havlik RJ, LaCroix AZ, Kleinman JC, Ingram DD, Harris T, Cornoni-Huntley J. Antihypertensive drug therapy and survival by treatment status in a national survey. Hypertension. 1989;13:I28-312.
5. Lehman ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med. 1992;9:114-119.
6. Laogun AA, Goslin RG. In vivo arterial compliance in man. Clin Phys Physiol Meas. 1982;3:201-212.
7. Benetos A, Laurent S, Asmar RG, Lacolley P. Large arterial stiffness in hypertension. J Hypertens Suppl. 1997;15:S89-S97.
8. Blacher J, Asmar R, Djane S, London GM, Safar ME. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive subject. Hypertension. 1999;33:1111-1117.
9. Cameron JD, Rajkumar C, Christophidis N, Jennings GL, Dart AM. Reduced systemic arterial compliance is associated with left ventricular hypertrophy and diastolic dysfunction in older people. J Am Geriatr Soc. 1997;45:803-808.
10. Lehman ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med. 1992;9:114-119.
11. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation. 2001;103:987-992.
12. Balcher J, Guerin AP, Pannier B. Impact of aortic stiffness on survival in End-Stage renal disease. Circulation. 1999;99:2434-2439.
13. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens. 1999;17:S41-S44.
14. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, et al. Vascular compliance and cardiovascular disease: a risk factor or a marker? Am J Hypertens. 1997;10:1175-1189.
15. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-592.
16. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17:37-42.
17. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002;15:1087-1091.
18. von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001;19:1813-1818.
19. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14:541-546.
20. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens. 2002;15:1092-1095.
21. Senn S. Cross-over trials in clinical research. Chichester: Wiley; 1993. p. 60-69, 100-101.
22. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: Validation and clinical application studies. Hypertension. 1995;26:485-490.
23. Knudsen ST, Andersen NH, Poulsen SH, et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALML II study post-hoc analysis. Am J Hypertens. 2008;21:133.
24. Khder Y, Bray-Desboscs L, Aliot E, Zannad F. Effects of blood pressure control on radial artery diameter and compliance in hypertensive patients. Am J Hypertens. 1997;10:269-274.
25. Slama M, Safavian A, Tual JL, Laurent S, Safar ME. Effects of antihypertensive drugs on large artery compliance. Neth J Med. 1995;47:162-218.
26. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
27. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997;349:747-752.
28. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
29. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799-805.
30. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep. 2002;4:202-210.